

Express Mail Label No.: EU 866640244 US
Date of Deposit: January 15, 2003

Attorney Docket No. 21402-224AE (Cura 524AE)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JAN 17 2003
TECH CENTER 1600/2900

APPLICANTS : Padigaru, et al.
SERIAL NUMBER : 10/024,399 EXAMINER : Not Yet Assigned
FILING DATE : December 18, 2001 ART UNIT : 1614
FOR : Novel Proteins and Nucleic Acids Encoding Same

BOX IDS

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of cited references B1-B3 and C14-C16; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 21402-224AE (Cura 524AE). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529
Flora W. Feng, Reg. No. 51,673
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: January 15, 2003



30623

PATENT TRADEMARK OFFICE

Express Mail Label No.: EU 866640244 US
Date of Deposit: January 15, 2003

Attorney Docket No.: 21402-224AE (Cura-524AE)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Padigaru, et al.

SERIAL NUMBER: 10/024,399

EXAMINER: Not Yet Assigned

FILING DATE: December 18, 2001

ART UNIT: 1614

FOR: Novel Proteins and Nucleic Acids Encoding Same

BOX IDS

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Padigaru, et al.
U.S.S.N.: 10/024,399

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21402-224AE (Cura-524AE).

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529

Flora W. Feng, Reg. No. 51,673

Attorneys for Applicants

MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: January 15, 2003

NYC 254010v1

Express Mail No. EU 866640244 US

Date of Deposit: January 15, 2003

RECEIVED

JAN 17 2003

Please type a plus sign (+) in this box



TECH CENTER 16002000

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/024,399
	Filing Date	12/18/01
	First Named Inventor	Padigaru
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	21402-224AE (Cura-524AE)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1	WO	95/18140	Yeda Research and Development Co. Ltd.	July 6, 1995	X	
	B2	WO	99/28470	Millenium Pharmaceuticals, Inc.	June 10, 1999	X	
	B3	WO	01/64879	Curagen Corporation	September 7, 2001	X	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C14	Database EMBL Accession No: AP000916 .					
	C15	Ramking, K. et al. (1993): "Cloning and Expression of Odorant Receptors." <i>Nature</i> 361 : 353-356.					
	C16	Invitation to Pay Additional Fees for PCT/US01/49077, mailed December 27, 2002.					

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

NYC 254011v1